Evaluating Biomarkers for Guiding Treatment Decisions.
The genetic revolution is expected to lead to improved targeting of new and existing forms of treatment. Rather than a one-size-fits-all blockbuster strategy in battling disease with drugs and other interventions, a more precise approach is becoming available, one in which treatment is only offered to those likely to benefit. The identification of those likely to benefit from treatment could be based on one or more biomarkers, but in an era where medical decisions aim to be evidence-based, the use of treatment selection markers should not just be based on hope and optimism, but on solid data from sound research. The performance of the treatment selection marker should be expressed in quantitative terms, similar to the way we express the clinical performance of diagnostic markers, or the performance of prognostic markers.
Department of Clinical Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, University of Amsterdam , The Netherlands.
Patrick M
PM
Bossuyt
Department of Clinical Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, University of Amsterdam , The Netherlands.
Tajik
T
Parvin
biomarker; clinical effectiveness; evidence-based medicine; medical test evaluation
PLoS Med. 2012;9(4):e1001208
22545024
N Engl J Med. 1980 May 15;302(20):1109-17
7366635
J Clin Oncol. 2005 Mar 20;23(9):2020-7
15774793
Int J Biostat. 2014;10(1):99-121
24695044
Lung Cancer. 2011 May;72(2):213-8
20817340
Eur J Cancer. 2010 Jul;46(10):1800-7
20137908
Am J Obstet Gynecol. 2012 Oct;207(4):276.e1-10
22901981
Clin Chim Acta. 2014 Jan 1;427:49-57
24076255
Semin Nucl Med. 1978 Oct;8(4):324-35
754287
Patient Educ Couns. 2008 Aug;72(2):239-45
18434070
PLoS Med. 2014 May 13;11(5):e1001645
24824338
Ann Intern Med. 2011 Feb 15;154(4):253-9
21320940
Biostatistics. 2015 Apr;16(2):383-99
25190512
BJOG. 2014 Sep;121(10):1263-72; discussion 1273
24862166